ABSTRACT
Olanzapine is a second-generation antipsychotic, which is also used as a mood stabilizer. We report a case of a 33-year-old psychiatric patient, with bipolar affective disorder, who developed anaphylaxis as a late reaction to olanzapine. This case report shows the possibility, although rare, of a severe late anaphylactic reaction to olanzapine.
Subject(s)
Anaphylaxis/chemically induced , Antipsychotic Agents/adverse effects , Benzodiazepines/adverse effects , Bipolar Disorder/drug therapy , Adult , Anaphylaxis/etiology , Anaphylaxis/therapy , Antipsychotic Agents/therapeutic use , Benzodiazepines/therapeutic use , Dopamine Antagonists/adverse effects , Dopamine Antagonists/therapeutic use , Drug Hypersensitivity/physiopathology , Female , Humans , Olanzapine , Serotonin Antagonists/adverse effects , Serotonin Antagonists/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Up to 100% relapse rate after successful electroconvulsive therapy (ECT) poses a challenge for patients and psychiatrists. The aim of the study was to evaluate the outcome of patients affected by major depression after the successful course of acute ECT. METHODS: 84 patients recruited in a randomized double blind multicenter study designed to investigate the optimal stimulation placement in acute ECT had a follow up under naturalistic conditions between the 5th and 7th month. Outcome, maintenance therapy and patients; attitude were evaluated with semi structured questionnaires by patients and the study raters. RESULTS: 82.14% (68/84) questionnaires of the patients and 83.3% (70/84) of the rater were returned. 98% of the patients had at least one antidepressant; only in 23% (20/68) lithium was prescribed. 35% (7/20) of the patients with lithium and 57% (16/28) without lithium had a relapse within the first 6 months (OR 0.6) in a median of 2.5 months. Only one institution offered maintenance ECT in 8.3% (7/84) patients. For 52.2% of the patients ECT was a helpful treatment an 49.3% would recommend the therapy to their relatives. The vast majority (59.4%) wishes a better information about the ECT and 21.4% feel frightening about the therapy. CONCLUSIONS: The results show a high relapse rate and highlight the meaning of maintenance medication especially for a lithium combination therapy, as stated before. In regard to the subjective sensation the patients claim a better education about the ECT and anyway one of four patients feel frightening about the therapy.
Subject(s)
Depressive Disorder, Major/therapy , Adult , Antidepressive Agents/therapeutic use , Combined Modality Therapy , Depressive Disorder, Major/diagnosis , Double-Blind Method , Electroconvulsive Therapy/adverse effects , Electroconvulsive Therapy/psychology , Female , Follow-Up Studies , Humans , Lithium Carbonate/therapeutic use , Male , Middle Aged , Patient Readmission , Patient Satisfaction , Recurrence , RetreatmentABSTRACT
OBJECTIVE: Therapeutic drug monitoring (TDM) of the new generation antidepressants is subject of controversial discussion. Nonetheless, TDM may safeguard against drug-drug interactions, can be used to control compliance and is valuable in the investigation of overdose. METHOD: The aim of this prospective study was to investigate serum levels of trazodone when prescribed as monotherapy or when used in combination with the selective serotonin reuptake inhibitors citalopram and fluoxetine in a simultaneous assay using high-performance liquid chromatography (HPLC). Over a 1-year period, we studied 97 patients (63 females) with depressive syndrome who were subdivided into 3 main diagnostic groups. Fifty-two patients were smokers, the mean age was 39.9 years and the mean weight was 72.4 kg; 40 patients were taking trazodone alone, 41 trazodone in combination with citalopram and 16 patients trazodone in combination with fluoxetine. RESULTS: The use of citalopram and fluoxetine in combination with trazodone had no significant impact on trazodone serum levels, and the same was true for differences in body weight and smoking behavior. On the other hand, age and sex had a significant influence on the pharmacokinetic pattern of trazodone, causing higher concentrations in females and in older patients. Since the polypharmacy investigated did not change the serum levels of trazodone, we assume that there is no metabolic interaction between trazodone and citalopram and trazodone and fluoxetine. We observed none of the adverse effects which might have been expected, including dizziness, severe headache, daytime sedation, fatigue or the serotonin syndrome even in a mild form. CONCLUSION: A "double-tracked" antidepressive treatment using trazodone and the SSRIs citalopram and fluoxetine is associated with a wide safety margin.
